ACTU vs KEY · $49.0M cap vs P/E 13, rev $7.51B
Actuate Therapeutics, Inc. Common stock (ACTU) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
KeyCorp (KEY) is a banks - regional company listed on US.
ACTU does not have a complete income-statement cache yet.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
ACTU currently screens at market cap $49.0M. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the ACTU and KEY stock pages for the full models.
Not investment advice.